This website is intended for Irish patients who have been prescribed SONDELBAY® (teriparatide).
Not an Irish patient prescribed SONDELBAY®? Click HERE.
Information placed on this digital platform is not intended as a substitute for consultation with your healthcare professional.
Please consult your healthcare professional for further information.
Please carefully read the Patient Information Leaflet in your box of Sondelbay®.

Sondelbay
Sondelbay

This website is intended for Irish patients who have been prescribed SONDELBAY® (teriparatide).
Not an Irish patient prescribed SONDELBAY®? Click HERE.
Information placed on this digital platform is not intended as a substitute for consultation with your healthcare professional.
Please consult your healthcare professional for further information.
Please carefully read the Patient Information Leaflet in your box of Sondelbay®.

Introducing SONDELBAY®
(teriparatide)

SONDELBAY® contains the active substance teriparatide.¹

Your doctor has prescribed SONDELBAY® to treat osteoporosis. Osteoporosis is a disease that causes your bones to become thin and fragile.¹

Osteoporosis can affect many people, but it is especially common in women after the menopause.² It can also occur in men and is common in patients receiving corticosteroids.³

Indicated in adults for:¹
• Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures, but not hip fractures, has been demonstrated.
• Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

Introducing SONDELBAY®
(teriparatide)

SONDELBAY® contains the active substance teriparatide.¹

Your doctor has prescribed SONDELBAY® to treat osteoporosis. Osteoporosis is a disease that causes your bones to become thin and fragile.¹

Osteoporosis can affect many people, but it is especially common in women after the menopause.² It can also occur in men and is common in patients receiving corticosteroids.³

Indicated in adults for:¹
• Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures, but not hip fractures, has been demonstrated.
• Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

Sondelbay background image of mature woman with gray hair

References: 1. SONDELBAY® package leaflet: Information for the user. 2. Kanis JA, et al. Osteoporos Int 2019;30:3-44. 3. Manolagas SC. Endocr Rev 2010;31(3):266-300.